1362 related articles for article (PubMed ID: 16314620)
1. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
5. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
9. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
12. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S
J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158
[TBL] [Abstract][Full Text] [Related]
16. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Crawford BS; McNulty RM; Kraut EH; Turowski RC
Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Lazarovici TS; Yahalom R; Taicher S; Elad S; Hardan I; Yarom N
J Oral Maxillofac Surg; 2009 Apr; 67(4):850-5. PubMed ID: 19304045
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Clarke BM; Boyette J; Vural E; Suen JY; Anaissie EJ; Stack BC
Otolaryngol Head Neck Surg; 2007 Mar; 136(3):396-400. PubMed ID: 17321866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
